ADMA Biologics-Why Adma Biologics (ADMA) Outpaced the Stock Market Today

Group 1 - Adma Biologics closed at $18.67, with a +1.3% increase, outperforming the S&P 500's gain of 0.64% [1] - The stock has gained 15.91% over the past month, contrasting with the Medical sector's loss of 0.88% and the S&P 500's loss of 7.69% [1] Group 2 - The upcoming earnings release is expected to show an EPS of$ 0.16, representing a 100% increase from the prior-year quarter, with quarterly revenue projected at $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of$ 0.70 per share and revenue of $495.8 million, indicating changes of +42.86% and +16.26% respectively from last year [3] Group 3 - Recent modifications to analyst estimates for Adma Biologics reflect short-term business trends, with positive revisions indicating a favorable business outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Adma Biologics as 2 (Buy), with a 1.46% rise in the Zacks Consensus EPS estimate over the past month [5][6] Group 4 - Adma Biologics has a Forward P/E ratio of 26.52, which is a premium compared to the industry's average Forward P/E of 19.99 [7] - The Medical - Biomedical and Genetics industry holds a Zacks Industry Rank of 73, placing it in the top 30% of over 250 industries [7][8]